Lead
The American Cancer Society’s latest U.S. cancer statistics, released this week, report that 70 percent of patients diagnosed between 2015 and 2021 survived at least five years, up from 49 percent in the mid 1970s. The finding marks a major improvement driven by better treatments, earlier detection and reduced tobacco use. At the same time, the report warns that overall cancer incidence continues to rise for several common cancers and that stark mortality gaps persist for some populations. The balance of progress and new threats frames urgent questions about funding, access and equity in the years ahead.
Key Takeaways
- The five-year overall cancer survival rate in the United States reached 70 percent for diagnoses from 2015 to 2021, up from 49 percent in the mid 1970s.
- Survival gains since the mid 1990s were largest for many of the deadliest cancers, including multiple myeloma (32 percent to 62 percent), liver cancer (7 percent to 22 percent) and lung cancer (15 percent to 28 percent).
- Five-year survival for advanced cancers doubled from 17 percent to 35 percent for all cancers combined; locally advanced lung cancer rose from 20 percent to 37 percent, and metastatic lung cancer from 2 percent to 10 percent.
- Authors estimate that improved treatments, early detection and reduced smoking prevented about 4.8 million cancer deaths in the U.S. between 1991 and 2023.
- Despite overall gains, incidence is rising for breast, prostate, oral, pancreatic and endometrial cancers; liver cancer and melanoma are increasing among women.
- Native American people face the highest cancer mortality rates documented in the report, with death rates double those of white people for kidney, liver, stomach and cervical cancers.
- The report flags potential policy risks, noting proposed federal funding and staffing cuts could hinder future progress in cancer research and access to care.
Background
Tracking population-level cancer trends combines registry records and national mortality data to measure incidence and outcomes. The American Cancer Society analyzed recent cancer registry data alongside National Center for Health Statistics records to estimate incidence, staging and survival for the U.S. population. Historically, five-year survival has been a standard oncology benchmark because most cancers that remain recurrence-free at five years are unlikely to return, a metric used by major hospitals and cancer centers. Progress since the 1970s has reflected multiple drivers: new systemic therapies, targeted treatments, immunotherapies, screening programs for certain cancers and broad declines in smoking prevalence.
Nevertheless, those overall gains have not been uniform. Unequal access to screening, diagnostics, high-quality treatment and follow-up care creates persistent gaps by race, ethnicity and socioeconomic status. Structural factors including geography, insurance coverage and health system capacity affect how quickly medical advances translate into community-level survival. Simultaneously, environmental and lifestyle risk factors, from obesity to pollution exposures, are evolving and in some cases increasing the burden of specific cancers, altering the incidence landscape the U.S. faces today.
Main Event
The ACS report presents the first national estimate showing that 70 percent of people diagnosed with cancer between 2015 and 2021 survived at least five years. The organization reached this conclusion by combining the most recent population-based registry data with mortality statistics to calculate period survival estimates. The analysis highlights especially large improvements for cancers once considered highly lethal: multiple myeloma survival rose from 32 percent to 62 percent over the analysis window, while liver cancer survival increased from 7 percent to 22 percent and lung cancer from 15 percent to 28 percent.
Advanced-stage survival also improved. For all cancers combined, five-year survival for advanced diagnoses doubled from 17 percent to 35 percent. Lung cancer patients diagnosed at a locally advanced stage saw five-year survival improve from 20 percent to 37 percent; those with metastatic lung cancer saw survival rise from 2 percent to 10 percent. The ACS authors attribute these gains to more effective therapies, better staging and wider use of systemic treatments, including targeted agents and immunotherapies for select tumors.
Despite these advances, the report projects persistent and growing burdens: more than 2 million new cancer diagnoses are estimated for 2026 in the U.S., with over 600,000 deaths expected that year. Incidence trends are upward for breast, prostate, oral, pancreatic and endometrial cancers, and several cancers show rising rates among women. The ACS team also flagged that proposed federal funding and staffing reductions could slow or reverse momentum in research and patient access if enacted.
Analysis & Implications
The jump to a 70 percent five-year survival rate is a clear signal that biomedical research and clinical innovation have saved many lives, turning some fatal cancers into manageable chronic conditions for many patients. Targeted therapies, immunotherapy, improvements in surgical techniques and better supportive care all contribute to longer survival. The prevention story is also strong: reduced smoking remains one of the single largest contributors to falling mortality for many cancer types.
But the simultaneous rise in incidence for several common cancers complicates the public health picture. Increased diagnoses may reflect an aging population and better detection, but they also track with rising obesity rates, environmental exposures and other risk factors that are not easily reversed. If incidence continues to climb, gains in survival may be eclipsed by larger numbers of new cases and the resource demands that follow.
Equity is a central implication. The report’s identification of Native American populations with substantially higher death rates for certain cancers underscores how access, socioeconomic conditions and historical barriers shape outcomes. Without targeted policy and programmatic interventions—improving screening access, expanding treatment capacity, and addressing social determinants—some groups will benefit less from scientific advances.
Finally, the policy environment matters. The report explicitly connects continued improvement to stable or increasing support for research, training and public health services. Proposed budget and staffing cuts at federal research agencies and health programs could reduce the pipeline of new therapies and the systems needed to deliver them broadly, potentially slowing future survival gains.
Comparison & Data
| Measure | Mid 1970s | 1990s | 2015–2021 |
|---|---|---|---|
| All-cancer five-year survival | 49% | ~60% (approx) | 70% |
| Multiple myeloma | — | ~32% | 62% |
| Liver cancer | — | 7% | 22% |
| Lung cancer | — | 15% | 28% |
The table above places the current 70 percent five-year survival in historical context and highlights cancers with the largest proportional gains. These numbers represent population-wide period survival estimates and do not replace individual prognoses, which vary by stage, comorbidity and treatment access. The doubling of advanced-stage survival for all cancers combined indicates that treatments for later-stage disease have become more effective, but absolute survival for many metastatic cancers remains low and a continuing public health challenge.
Reactions & Quotes
Lead authors and organizational leaders emphasized both celebration and caution. The quotes below are short extracts presented with context.
This outcome is the result of decades of research that have transformed many cancers from fatal illnesses to manageable conditions for many patients.
Rebecca Siegel, ACS senior scientific director of cancer surveillance research
Siegel framed the 70 percent milestone as a cumulative victory for scientific progress, highlighting the role of research in expanding treatment options and improving survival for historically lethal cancers.
Lack of access to high-quality care and socioeconomic barriers continue to drive persistent racial disparities in cancer outcomes.
Ahmedin Jemal, ACS senior vice president of cancer surveillance, prevention, and health services research
Jemal emphasized that medical advances alone are insufficient without equitable access to screening, diagnostics and treatment across communities.
Threats to research funding and insurance access risk reversing progress and stalling future breakthroughs.
Shane Jacobson, CEO, American Cancer Society and Cancer Action Network
The ACS leadership warned that policy decisions about federal funding and health programs could materially affect the trajectory of cancer research and patient outcomes.
Unconfirmed
- The magnitude and timing of projected impacts from proposed federal research and staffing cuts remain uncertain until budgets are finalized and agency plans are enacted.
- The contribution of environmental exposures such as microplastics to recent incidence trends is under active study and not established as a primary driver for most cancer types.
- How quickly survival gains will translate to historically underserved communities depends on future policy actions and program deployment, which are not yet decided.
Bottom Line
The ACS report offers a clear reason for cautious optimism: population-level five-year survival for cancer in the United States has risen to 70 percent, a major milestone reflecting decades of research, prevention and clinical innovation. Those gains demonstrate that coordinated investment in science, public health and clinical care can deliver measurable extensions in life for many people with cancer.
At the same time, rising incidence for several cancers, persistent racial and ethnic mortality gaps, and threats to research funding and access mean the public health work is far from done. Sustaining and expanding progress will require targeted action on equity, continued investment in research, and policies that maintain access to prevention, early detection and high-quality treatment for all communities.
Sources
- Gizmodo — media report summarizing the American Cancer Society findings
- American Cancer Society — official organizational report and press materials
- National Center for Health Statistics — U.S. government mortality and registry data source
- Cleveland Clinic — clinical resource explaining five-year survival as a benchmark